National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients

HIV Med. 2007 Apr;8(3):186-91. doi: 10.1111/j.1468-1293.2007.00451.x.

Abstract

Objectives: The aim of the study was to explore the factors surrounding modification of the first antiretroviral (ARV) regimen where drug switch occurred 3 months or more after initiation. Reference was made to the British HIV Association (BHIVA) guidelines on HIV management.

Methods: A case note and questionnaire-based audit was carried out.

Results: Toxicity was the single most important reason for ARV change and was the only, or a contributory, cause in over half the patients. Virological failure, adherence issues, requirement for treatment simplification, and patient request were other significant reasons cited. In one-third of those with virological failure, six or more months had elapsed between first detection and the time of switching to a new ARV regimen.

Conclusions: This audit demonstrated broad adherence to the BHIVA guidelines, although the long time before switching ARVs in the setting of virological failure was of some concern, particularly given the continuing and significant occurrence of primary ARV resistance in the UK.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Antiretroviral Therapy, Highly Active / methods*
  • HIV / growth & development*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Practice Guidelines as Topic
  • United Kingdom
  • Viral Load

Substances

  • Anti-HIV Agents